SCHEMBL3353113

SCHEMBL3353113

Oc1cc2nnnn2c2ncccc12

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 10/20 0.36
L3MBTL1 Q9Y468 5/20 0.36
HSP90AA1 P07900 3/20 0.36
LMNA P02545 2/20 0.36
HTT P42858 2/20 0.36
MAPT P10636 2/20 0.36
IDO1 P14902 2/20 0.36
MPI P34949 1/20 0.36
BRD4 O60885 1/20 0.36
METAP2 P50579 1/20 0.36
METAP1 P53582 1/20 0.36
HSP90AB1 P08238 1/20 0.36
PSMB5 P28074 1/20 0.36
SLC6A2 P23975 1/20 0.36
FTO Q9C0B1 2/20 0.36
NPC1 O15118 3/20 0.35
RAB9A P51151 3/20 0.35
GAA P10253 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
NPSR1 Q6W5P4 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8145176 0.92 MIF (0.33) KDM4EL3MBTL1HSP90AA1LMNAHTT
SCHEMBL3354876 0.81 L3MBTL1 (0.39) KDM4EL3MBTL1HSP90AA1LMNAHTT
SCHEMBL842844 0.76 KDM4E (0.38) KDM4EL3MBTL1HSP90AA1LMNAHTT
SCHEMBL6098707 0.76 ALDH1A1 (0.43) KDM4ELMNAMAPTNPC1RAB9A
SCHEMBL3358787 0.69 KDM5A (0.40) KDM4EMAPTIDO1SMN1; SMN2ALDH1A1
SCHEMBL3356207 0.68 MAPK1 (0.36) KDM4EL3MBTL1HSP90AA1LMNAHTT
SCHEMBL3354370 0.66 S100A4 (0.42) KDM4EL3MBTL1HSP90AA1LMNAHTT
SCHEMBL3514617 0.66 FEN1 (0.47) KDM4EL3MBTL1HSP90AA1LMNAHTT
SCHEMBL2409501 0.65 FEN1 (0.57) MAPTSMN1; SMN2KMT2AALDH1A1FEN1
SCHEMBL5871967 0.65 FEN1 (0.54) KDM4EHTTMAPTSLC6A2FTO

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8329721-B2 Hydroxy and alkoxy substituted 1H-imidazonaphthyridines and methods 3M INNOVATIVE PROPERTIES COMPANY (US) 2012-12-11 US disclosed
US-8329721-B2 Hydroxy and alkoxy substituted 1H-imidazonaphthyridines and methods 3M INNOVATIVE PROPERTIES COMPANY (US) 2012-12-11 US disclosed
US-7678918-B2 Intermediates for imidazonaphthyridines 3M INNOVATIVE PROPERTIES COMPANY (US) 2010-03-16 US disclosed
US-7678918-B2 Intermediates for imidazonaphthyridines 3M INNOVATIVE PROPERTIES COMPANY (US) 2010-03-16 US disclosed
US-20090298821-A1 HYDROXY AND ALKOXY SUBSTITUTED IH-IMIDAZONAPHTHYRIDINES AND METHODS PFIZER INC. 2009-12-03 US disclosed
US-20090298821-A1 HYDROXY AND ALKOXY SUBSTITUTED IH-IMIDAZONAPHTHYRIDINES AND METHODS PFIZER INC. 2009-12-03 US disclosed
US-20090270443-A1 1-AMINO IMIDAZO-CONTAINING COMPOUNDS AND METHODS COLEY PHARMACEUTICAL GROUP, INC. 2009-10-29 US disclosed
US-20080091010-A1 Intermediates for imidazonaphthyridines GRACEWAY PHARMACEUTICALS, LLC (US) 2008-04-17 US disclosed
US-20080091010-A1 Intermediates for imidazonaphthyridines GRACEWAY PHARMACEUTICALS, LLC (US) 2008-04-17 US disclosed
US-7335773-B2 Intermediates for imidazonaphthyridines GRACEWAY PHARMACEUTICALS, LLC (US) 2008-02-26 US disclosed
US-6624172-B2 Imidazonaphthyridine and tetrahydroimidazonaphthyridine compounds induce the biosynthesis of cytokines such as interferon and tumor necrosis factor, and useful as viricides and antitumor agents 3M INNOVATIVE PROPERTIES COMPANY 2003-09-23 US disclosed
US-20030096998-A1 Imidazonaphtyridines 3M INNOVATIVE PROPERTIES COMPANY 2003-05-22 US disclosed
US-20030083500-A1 Imidazonaphthyridines 3M INNOVATIVE PROPERTIES COMPANY 2003-05-01 US disclosed
US-6518280-B2 Antiviral and antitumor properties; immunomodulators and for inducing cytokine biosynthesis in animals 3M INNOVATIVE PROPERTIES COMPANY 2003-02-11 US disclosed
US-6514985-B1 Induce the biosynthesis of cytokines such as interferon and tumor necrosis factor; exhibit antiviral and antitumor properties 3M INNOVATIVE PROPERTIES COMPANY 2003-02-04 US disclosed
US-20020173653-A1 Imidazonaphthyridines 3M INNOVATIVE PROPERTIES COMPANY 2002-11-21 US disclosed
US-20020173654-A1 Imidazonaphthyridines 3M INNOVATIVE PROPERTIES COMPANY 2002-11-21 US disclosed
US-6194425-B1 VIRICIDES, ANTITUMOR AGENTS 3M INNOVATIVE PROPERTIES COMPANY 2001-02-27 US disclosed
EP-1040112-A1 IMIDAZONAPHTHYRIDINES AND THEIR USE IN INDUCING CYTOKINE BIOSYNTHESIS MINNESOTA MINING AND MANUFACTURING COMPANY (US) 2000-10-04 EP disclosed
WO-1999029693-A1 IMIDAZONAPHTHYRIDINES AND THEIR USE IN INDUCING CYTOKINE BIOSYNTHESIS MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1999-06-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080091010-A1 Intermediates for imidazonaphthyridines IFNG, IRF3, MAVS KDM4E 4562/4885L3MBTL1 3804/4885HSP90AA1 2420/4885
US-20030083500-A1 Imidazonaphthyridines IFNG, IRF3, IFNAR1 KDM4E 4437/4885L3MBTL1 4154/4885HSP90AA1 2193/4885
US-20090298821-A1 HYDROXY AND ALKOXY SUBSTITUTED IH-IMIDAZONAPHTHYRIDINES AND METHODS IL2, IL4, IFNG KDM4E 2756/4885L3MBTL1 4315/4885HSP90AA1 904/4885
US-20030096998-A1 Imidazonaphtyridines IFNG, IRF3, IFNAR1 KDM4E 4492/4885L3MBTL1 4141/4885HSP90AA1 2222/4885
US-20090270443-A1 1-AMINO IMIDAZO-CONTAINING COMPOUNDS AND METHODS IL2, IL4I1, IFNG KDM4E 3088/4885L3MBTL1 2506/4885HSP90AA1 1164/4885
US-20020173653-A1 Imidazonaphthyridines IFNG, IRF3, IFNAR1 KDM4E 4437/4885L3MBTL1 4154/4885HSP90AA1 2193/4885
US-20020173654-A1 Imidazonaphthyridines IFNG, IRF3, IFNAR1 KDM4E 4437/4885L3MBTL1 4154/4885HSP90AA1 2193/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.